(A) Duration of response (DOR), minimal response or better. The median DOR for all 30 responders was 19.5 months (95% CI, 11.5 to 26.7 months; range, 5 to 30 months). (B) The median progression-free survival (PFS) is 15.6 months (95% CI, 11.2 to 21.1 months), with estimated 12-month and 18-month PFS of 58% (95% CI, 39% to 75%) and 45% (95% CI, 27% to 63%). (C) The median time to next therapy was 17.6 months (range, 1 to 25 months).